Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.

Parrini M, Ghezzi D, Deidda G, Medrihan L, Castroflorio E, Alberti M, Baldelli P, Cancedda L, Contestabile A.

Sci Rep. 2017 Dec 4;7(1):16825. doi: 10.1038/s41598-017-17201-8.

2.

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.

Stringer M, Goodlett CR, Roper RJ.

Mol Genet Genomic Med. 2017 Sep 20;5(5):451-465. doi: 10.1002/mgg3.334. eCollection 2017 Sep. Review.

3.

Activity-Dependent Dysfunction in Visual and Olfactory Sensory Systems in Mouse Models of Down Syndrome.

William CM, Saqran L, Stern MA, Chiang CL, Herrick SP, Rangwala A, Albers MW, Frosch MP, Hyman BT.

J Neurosci. 2017 Oct 11;37(41):9880-9888. doi: 10.1523/JNEUROSCI.1045-17.2017. Epub 2017 Sep 12.

PMID:
28899917
4.

Enhanced derivation of human pluripotent stem cell-derived cortical glutamatergic neurons by a small molecule.

Cao SY, Hu Y, Chen C, Yuan F, Xu M, Li Q, Fang KH, Chen Y, Liu Y.

Sci Rep. 2017 Jun 12;7(1):3282. doi: 10.1038/s41598-017-03519-w.

5.

An interaction network of mental disorder proteins in neural stem cells.

Moen MJ, Adams HH, Brandsma JH, Dekkers DH, Akinci U, Karkampouna S, Quevedo M, Kockx CE, Ozgür Z, van IJcken WF, Demmers J, Poot RA.

Transl Psychiatry. 2017 Apr 4;7(4):e1082. doi: 10.1038/tp.2017.52.

6.

The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome.

Contestabile A, Magara S, Cancedda L.

Front Cell Neurosci. 2017 Mar 7;11:54. doi: 10.3389/fncel.2017.00054. eCollection 2017. Review.

7.

Down Syndrome: Current Status, Challenges and Future Perspectives.

Kazemi M, Salehi M, Kheirollahi M.

Int J Mol Cell Med. 2016 Summer;5(3):125-133. Epub 2016 Aug 10. Review.

8.

Trans-acting epigenetic effects of chromosomal aneuploidies: lessons from Down syndrome and mouse models.

Do C, Xing Z, Yu YE, Tycko B.

Epigenomics. 2017 Feb;9(2):189-207. doi: 10.2217/epi-2016-0138. Epub 2016 Dec 2. Review.

9.

Mouse-based genetic modeling and analysis of Down syndrome.

Xing Z, Li Y, Pao A, Bennett AS, Tycko B, Mobley WC, Yu YE.

Br Med Bull. 2016 Dec;120(1):111-122. Epub 2016 Oct 27. Review.

10.

Olig2 regulates Purkinje cell generation in the early developing mouse cerebellum.

Ju J, Liu Q, Zhang Y, Liu Y, Jiang M, Zhang L, He X, Peng C, Zheng T, Lu QR, Li H.

Sci Rep. 2016 Jul 29;6:30711. doi: 10.1038/srep30711.

11.

A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts.

Dell'Osso L, Del Grande C, Gesi C, Carmassi C, Musetti L.

Neuropsychiatr Dis Treat. 2016 Jul 11;12:1687-703. doi: 10.2147/NDT.S106479. eCollection 2016. Review.

12.

The HSA21 gene EURL/C21ORF91 controls neurogenesis within the cerebral cortex and is implicated in the pathogenesis of Down Syndrome.

Li SS, Qu Z, Haas M, Ngo L, Heo YJ, Kang HJ, Britto JM, Cullen HD, Vanyai HK, Tan SS, Chan-Ling T, Gunnersen JM, Heng JI.

Sci Rep. 2016 Jul 11;6:29514. doi: 10.1038/srep29514.

13.

Dishing out mini-brains: Current progress and future prospects in brain organoid research.

Kelava I, Lancaster MA.

Dev Biol. 2016 Dec 15;420(2):199-209. doi: 10.1016/j.ydbio.2016.06.037. Epub 2016 Jul 9. Review.

14.

Absence of Prenatal Forebrain Defects in the Dp(16)1Yey/+ Mouse Model of Down Syndrome.

Goodliffe JW, Olmos-Serrano JL, Aziz NM, Pennings JL, Guedj F, Bianchi DW, Haydar TF.

J Neurosci. 2016 Mar 9;36(10):2926-44. doi: 10.1523/JNEUROSCI.2513-15.2016.

15.

Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.

Olmos-Serrano JL, Kang HJ, Tyler WA, Silbereis JC, Cheng F, Zhu Y, Pletikos M, Jankovic-Rapan L, Cramer NP, Galdzicki Z, Goodliffe J, Peters A, Sethares C, Delalle I, Golden JA, Haydar TF, Sestan N.

Neuron. 2016 Mar 16;89(6):1208-1222. doi: 10.1016/j.neuron.2016.01.042. Epub 2016 Feb 25.

16.

Genetic dissection of Down syndrome-associated congenital heart defects using a new mouse mapping panel.

Lana-Elola E, Watson-Scales S, Slender A, Gibbins D, Martineau A, Douglas C, Mohun T, Fisher EM, Tybulewicz VLj.

Elife. 2016 Jan 14;5. pii: e11614. doi: 10.7554/eLife.11614.

17.

Altered intrinsic and network properties of neocortical neurons in the Ts65Dn mouse model of Down syndrome.

Cramer NP, Xu X, F Haydar T, Galdzicki Z.

Physiol Rep. 2015 Dec;3(12). pii: e12655. doi: 10.14814/phy2.12655. Epub 2015 Dec 22.

18.

Timing of therapies for Down syndrome: the sooner, the better.

Stagni F, Giacomini A, Guidi S, Ciani E, Bartesaghi R.

Front Behav Neurosci. 2015 Oct 6;9:265. doi: 10.3389/fnbeh.2015.00265. eCollection 2015. Review.

19.

DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.

Najas S, Arranz J, Lochhead PA, Ashford AL, Oxley D, Delabar JM, Cook SJ, Barallobre MJ, Arbonés ML.

EBioMedicine. 2015 Jan 17;2(2):120-34. doi: 10.1016/j.ebiom.2015.01.010. eCollection 2015.

20.

Deletion of the App-Runx1 region in mice models human partial monosomy 21.

Arbogast T, Raveau M, Chevalier C, Nalesso V, Dembele D, Jacobs H, Wendling O, Roux M, Duchon A, Herault Y.

Dis Model Mech. 2015 Jun;8(6):623-34. doi: 10.1242/dmm.017814. Epub 2015 Apr 16.

Supplemental Content

Support Center